Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC
Clinical trial NCT07643350 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07643350
- Sponsor
- The Third Xiangya Hospital of Central South University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-15
- Primary completion
- 2029-05-15
- Enrollment
- 152
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.